Novartis Phase 3 Trial of Pelacarsen Fails to Meet Cardiovascular Endpoint
Here's what it means for you.
The failure of this trial could impact future cardiovascular treatment options and investment strategies in the pharmaceutical sector.
What happened
On September 4, 2026, Novartis announced that its Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing major cardiovascular events.
The Context
- Elevated Lp(a) is a significant risk factor for cardiovascular disease, affecting about 20% of the global population, yet no targeted therapies exist.
- Pelacarsen was designed to lower Lp(a) levels in patients already on standard lipid-lowering treatments, aiming to reduce residual cardiovascular risk.
- Despite lowering Lp(a) levels, the trial showed no corresponding decrease in cardiovascular events, raising questions about the efficacy of Lp(a) reduction alone.
The Number
patients were enrolled in the Lp(a)HORIZON Phase 3 trial, highlighting the scale of investment and research in addressing cardiovascular risks.
Takeaway
As Novartis prepares to present full trial data at an upcoming medical congress, the implications for future cardiovascular therapies and investments remain to be seen.
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
Novartis announced that its Phase 3 clinical trial for the heart drug Pelacarsen did not achieve its primary goal of reducing cardiovascular events such as heart attacks and strokes. This outcome has raised concerns among stakeholders who anticipated...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
Novartis's highly anticipated cholesterol drug, Pelacarsen, has failed to demonstrate a reduction in severe cardiovascular outcomes, such as heart attacks and strokes, in a Phase 3 clinical trial. This disappointing result has raised concerns among c...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Novartis announced that its heart disease drug Pelacarsen failed to meet its primary endpoint in a Phase 3 clinical trial, leading to a decline in the company's shares during after-hours trading. The trial did not demonstrate a significant reduction ...